News summary

From susceptibility to clinical action in fibrotic interstitial lung disease: determinants, progression, and evidence boundaries

Source: Frontiers - Health • Published: 02 Nov 2026, 00:00

Summarized by Masters of Longevity from Frontiers - Health.

Narrative review maps mechanisms, diagnostics, and evidence guiding fibrotic ILD care.

From susceptibility to clinical action in fibrotic interstitial lung disease: determinants, progression, and evidence boundaries
Key Takeaways
  • Mouse and cell models are the main causal evidence source.
  • Human tissue studies are relevant but rarely show temporal sequence.
  • Randomized trials support therapy for defined IPF and progressive groups.
Read the full article at Frontiers - Health ↗

Continue exploring

Recommended MoL Picks

MoL PickCreatine and Cancer: Why New Mouse Studies Point in Opposite DirectionsCreatine strengthened antitumour immune cells in one mouse study—and promoted metastasis through platelets in another. The apparent contradiction reveals why neither result is a supplement recommendation.MoL PickThe Next Obesity-Drug Race Is About What Weight You LoseRegeneron’s myostatin and activin A antibodies point to a sharper question for the GLP-1 era: not whether people can lose more weight, but whether medicine can preserve the tissue that makes weight loss healthier.MoL PickPlan Your Health Tests in Three MinutesThe free Personal Health Diagnostics Planner turns a short questionnaire into a ranked, personalised PDF: a clearer starting point for deciding which health checks deserve attention now.